tbuckley/cabot-search huggingface dataset:
Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis
Authors: Emma E van Daalen, Raffaella Rizzo, Andreas Kronbichler, Ron Wolterbeek, Jan A Bruijn, David R Jayne, Ingeborg M Bajema, Chinar Rahmattulla
Journal: Annals of the Rheumatic Diseases (2016)

Objectives Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated with cyclophosphamide have an increased malignancy risk compared with the general population. We investigated whether treatment with rituximab instead of cyclophosphamide has decreased the malignancy risk in patients with AAV. Methods The study included patients with AAV treated at a tertiary vasculitis referral centre between 2000 and 2014. The malignancy incidence in these patients was compared with the incidence in the general population by calculating standardised incidence ratios (SIRs), adjusted for sex, age and calendar year. Malignancy incidence was compared between rituximab-treated and cyclophosphamide-treated patients. Results Of the 323 included patients, 33 developed a total of 45 malignancies during a mean follow-up of 5.6 years. This represented a 1.89-fold increased (95% CI 1.38 to 2.53) malignancy risk, and a non-significantly increased risk if non-melanoma skin cancer was excluded (SIR, 1.09; 95% CI 0.67 to 1.69). The risk of non-melanoma skin cancer was 4.58-fold increased (95% CI 2.96 to 6.76). Cyclophosphamide-treated patients had an increased malignancy risk compared with the general population (SIR, 3.10; 95% CI 2.06 to 4.48). In contrast, rituximab-treated patients had a malignancy risk similar to the general population (SIR, 0.67; 95% CI 0.08 to 2.43). The malignancy risk in cyclophosphamide-treated patients was 4.61-fold higher (95% CI 1.16 to 39.98) than in rituximab-treated patients. Conclusions The malignancy risk in patients with AAV was lower in rituximab-treated patients than in cyclophosphamide-treated patients. Notably, rituximab treatment was not associated with an increased malignancy risk compared with the general population. Rituximab could therefore be a safe alternative to cyclophosphamide in the treatment of AAV.
Apheresis of Hematopoietic Progenitor Cell (HPC) From Allogeneic Donors ≥60 Years of Age.
Authors: William E. Janssen, Darlene Rahn, Teresa Field, Mohamed A Kharfan-Dabaja, Ernesto Ayala, Jose L Ochoa, Martha Hackett, Claudio Anasetti, Hugo F. Fernandez
Journal: Blood (2009)
Duration to Engraftment Requires Significantly Much More Time in Myelodysplastic Syndrome (MDS) Patients as Compared to Acute Myeloid Leukemia (AML) Patients Following Allogeneic Stem Cell Transplantation.
Authors: Menachem Bitan, Michael Y. Shapira, Igor B. Resnick, Benjamin Gesundheit, Irena Zilberman, Aliza Ackerstein, Simcha Samuel, Sharon Elad, Shimon Slavin, Reuven Or
Journal: Blood (2005)
ADAMTS13 Reactive CD4+ T Cells Targeting CUB-2 Domain Derived Peptides in Autoimmune Thrombotic Thrombocytopenic Purpura
Authors: Fabian Verbij, Femke de Heij, Annelies Turksma, Paul Kaijen, Rob Fijnheer, Nicoletta Sorvillo, Anja ten Brinke, Jan Voorberg
Journal: Blood (2015)
A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling
Authors: Joanne M. Hildebrand, Zhenghua Luo, Michelle Manske, Steven Ziesmer, Tammy Price-troska, Wai Lin, Bruce Hostager, Susan Slager, Thomas E. Witzig, Stephen M. Ansell, James Cerhan, Gail Bishop, Anne J. Novak
Journal: Blood (2010)
Correlations Between Host Cellular Immune Responses and Adenovirus (AdV) Associated Complications in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Valérie Guérin, Jean-Hugues Dalle, Béatrice Pedron, Karima Yakouben, Debora Jorge Cordeiro, Lucas Peltier, Marie Ouachée-Chardin, Andre Baruchel, Ghislaine Sterkers
Journal: Blood (2009)
Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements
Authors: A Vardi, E Vlachonikola, M Karypidou, E Stalika, V Bikos, K Gemenetzi, C Maramis, A Siorenta, A Anagnostopoulos, S Pospisilova, N Maglaveras, I Chouvarda, K Stamatopoulos, A Hadzidimitriou
Journal: Leukemia (2016)
No Significant Expression of Wt1 Gene in Multiple Myeloma Patients at Diagnosis: Is Wt1 Gene Expression Useful Marker for Minimal Residual Disease in Multiple Myeloma?.
Authors: Yusuf Ozkul, Ahmet O. Caglayan, Ismail Kocyigit, Cetin Saatci, Hilal Akalin, Muzaffer Demir, Fevzi Altuntas, Mustafa Cetin, Bulent Eser, Leylagul Kaynar
Journal: Blood (2007)
The novel use of a biliary stent as a temporizing measure in the treatment of severe refractory esophageal stricture
Authors: Scott Steinberg, Joshua Anderson, Silvio de Melo
Journal: Endoscopy (2016)

Esophageal stricture is a narrowing of the esophageal lumen that may result from the use of external beam radiation therapy (EBRT) for the treatment of certain malignancies [1]. Endoscopic dilation is the standard of care; however, stenting is occasionally required. Most manufacturers make esophageal stents with a minimum outer diameter of 16 mm and few are available in smaller sizes [2]. Occasionally, strictures are so severe that the smallest esophageal stent that is commercially available is too large. An alternative method that has been reported is the off-label use of smaller biliary stents to treat proximal esophageal strictures [3].
Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A
Authors: Bryce A. Kerlin, Roshni Kulkarni, Beatrice Nolan, Michael Wang, K John Pasi, Raina Liesner, Simon Brown, Hideji Hanabusa, Ingrid Pabinger-Fasching, Elisa Tsao, Geoffrey Allen
Journal: Blood (2015)
Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial
Authors: Fabio Manfredini, Francesca Mallamaci, Graziella D’Arrigo, Rossella Baggetta, Davide Bolignano, Claudia Torino, Nicola Lamberti, Silvio Bertoli, Daniele Ciurlino, Lisa Rocca-Rey, Antonio Barillà, Yuri Battaglia, Renato Mario Rapanà, Alessandro Zuccalà, Graziella Bonanno, Pasquale Fatuzzo, Francesco Rapisarda, Stefania Rastelli, Fabrizio Fabrizi, Piergiorgio Messa, Luciano De Paola, Luigi Lombardi, Adamasco Cupisti, Giorgio Fuiano, Gaetano Lucisano, Chiara Summaria, Michele Felisatti, Enrico Pozzato, Anna Maria Malagoni, Pietro Castellino, Filippo Aucella, Samar Abd ElHafeez, Pasquale Fabio Provenzano, Giovanni Tripepi, Luigi Catizone, Carmine Zoccali
Journal: Journal of the American Society of Nephrology (2016)

Previous studies have suggested the benefits of physical exercise for patients on dialysis. We conducted the Exercise Introduction to Enhance Performance in Dialysis trial, a 6-month randomized, multicenter trial to test whether a simple, personalized walking exercise program at home, managed by dialysis staff, improves functional status in adult patients on dialysis. The main study outcomes included change in physical performance at 6 months, assessed by the 6-minute walking test and the five times sit-to-stand test, and in quality of life, assessed by the Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire. We randomized 296 patients to normal physical activity (control; n =145) or walking exercise ( n =151); 227 patients (exercise n =104; control n =123) repeated the 6-month evaluations. The distance covered during the 6-minute walking test improved in the exercise group (mean distance±SD: baseline, 328±96 m; 6 months, 367±113 m) but not in the control group (baseline, 321±107 m; 6 months, 324±116 m; P &lt;0.001 between groups). Similarly, the five times sit-to-stand test time improved in the exercise group (mean time±SD: baseline, 20.5±6.0 seconds; 6 months, 18.2±5.7 seconds) but not in the control group (baseline, 20.9±5.8 seconds; 6 months, 20.2±6.4 seconds; P =0.001 between groups). The cognitive function score ( P =0.04) and quality of social interaction score ( P =0.01) in the kidney disease component of the KDQOL-SF improved significantly in the exercise arm compared with the control arm. Hence, a simple, personalized, home-based, low-intensity exercise program managed by dialysis staff may improve physical performance and quality of life in patients on dialysis.
Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality.
Authors: Corey Cutler, Shuli Li, Haesook T. Kim, Rebecca Macdonell, Vincent Ho, Edwin Alyea, Stephanie J. Lee, Robert J. Soiffer, Joseph H. Antin
Journal: Blood (2005)
Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells
Authors: Karoline Veronika Gleixner, Lily L Remsing Rix, Christian Baumgartner, Uwe Rix, Alexander Gruze, Renata Anna Meyer, Winfried F. Pickl, Christian Sillaber, Martin Augustin, Jeff Till, Giulio Superti-Furga, Peter Valent
Journal: Blood (2008)
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
Authors: Lorenzo Falchi, Ahmed Sawas, Changchun Deng, Jennifer E. Amengual, Donald S. Colbourn, Emily A. Lichtenstein, Karen A. Khan, Lawrence H. Schwartz, Owen A. O’Connor
Journal: Journal of Hematology & Oncology (2016)

Options for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after brentuximab vedotin (Bv) and autologous stem cell transplantation (ASCT) are limited. Immune checkpoint inhibitors (ICI) are active in this population but rarely induce complete response (CR). Ten patients with R/R cHL after ASCT and Bv received pembrolizumab (n = 8) or nivolumab (n = 2). Five had been previously exposed to 5-azacitidine on a phase 1 study. Among nine evaluable patients, seven (78%) achieved CR, one partial response, and one reduction of tumor burden. All five patients who had received 5-azacitidine prior to ICI achieved CR, while only two of four who did not receive prior 5-azacitidine achieved CR. At a median follow-up of 9.9 months [0.5-14.3], eight patients are alive and five are still receiving treatment. We documented an unprecedented CR rate after ICI in patients with R/R cHL. We hypothesize that hypomethylating agents might have an immune priming effect and enhance the efficacy of ICI.
Radioisotope Synovectomy for Treating Chronic Synovitis in Inhibitor Patients with Hemophilia.
Authors: Kaan Kavakli, Semih Aydogdu, Yusuf Duman, Memduh Taner, Guray Saydam, Kazim Capaci, Aysenur Oktay, Can Balkan, Deniz Yilmaz
Journal: Blood (2006)
A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens.
Authors: Januario E. Castro, Olivier J. Loria, Robier A. Aguillon, Danelle James, Cesar A. Llanos, Laura Rassenti, Brian A. Wood, Jon T. Homlund, Thomas J. Kipps
Journal: Blood (2007)
Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404
Authors: Sandra J. Horning, Malik E. Juweid, Heiko Schoder, Gregory Wiseman, Alex McMillan, Lode J. Swinnen, Ranjana Advani, Randy D. Gascoyne, Andrew Quon
Journal: Blood (2008)
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics
Authors: Philippe Moreau, Ievgenii I Karamanesht, Natalia Domnikova, Maryna Y Kyselyova, Kateryna Vilchevska, Vadim A Doronin, Alexander Schmidt, Cyrille Hulin, Xavier Leleu, Dixie-Lee Esseltine, Karthik Venkatakrishnan, Donna M Skee, Huaibao Feng, Suzette Girgis, Andrew Z Cakana, William M Deraedt, Thierry Facon
Journal: Blood (2011)
Hypoxia-Inducible Factor (HIF)-1alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo
Authors: Paola Storti, Valentina Marchica, Denise Toscani, Irma Airoldi, Sophie Maiga, Marina Bolzoni, Nicoletta Campanini, Eugenia Martella, Cristina Mancini, Valentina Ferri, Gaetano Donofrio, Martine Amiot, Franco Aversa, Nicola Giuliani
Journal: Blood (2015)
Multidrug Resistance-1 Gene Polymorphism Associated with the Outcomes after Allogeneic HLA-Identical Stem Cell Transplantation.
Authors: Dong Hwan Kim, Seok Bong Jeon, Jin Ho Baek, Nan Young Lee, Jong Gwang Kim, Sang Kyun Sohn, Jang Soo Suh, Young Rok Do, Ki Kyung Kwon
Journal: Blood (2005)
Outcomes Of Relapse Of AML Post Allogeneic Transplantation In The Era Of Hypomethylating Agents: An Analysis Of 162 Allogeneic Transplants From a Single Center
Authors: Justin LaPorte, Xu Zhang, Zaamin Hussain, Stacey Brown, Connie A. Sizemore, Melissa Sanacore, Ronald Mihelic, Mindy Leech, Lawrence E. Morris, H. Kent Holland, Scott R. Solomon, Asad Bashey
Journal: Blood (2013)
Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality
Authors: Juan Jesús Carrero, Morgan E. Grams, Yingying Sang, Johan Ärnlöv, Alessandro Gasparini, Kunihiro Matsushita, Abdul R. Qureshi, Marie Evans, Peter Barany, Bengt Lindholm, Shoshana H. Ballew, Andrew S. Levey, Ron T. Gansevoort, Carl G. Elinder, Josef Coresh
Journal: Kidney International (2016)
In Vitro and in Vivo Characterization of Human Embryonic Stem Cell- Derived CD34+ Cells That Function as Pericytes with Endothelial Cell and Smooth Muscle Cell Potential
Authors: Katherine L. Hill, Petra Obrtlikova, Diego F Alvarez, Judy A King, Qinglu Li, Jianyi Zhang, Dan S. Kaufman
Journal: Blood (2008)
Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma
Authors: Thomas Seisen, Tarun Jindal, Patrick Karabon, Akshay Sood, Joaquim Bellmunt, Morgan Rouprêt, Jeffrey J. Leow, Malte W. Vetterlein, Maxine Sun, Shaheen Alanee, Toni K. Choueiri, Quoc-Dien Trinh, Mani Menon, Firas Abdollah
Journal: European Urology (2016)
Health Cards by Google: dermatologist review of the inclusivity and utility of the medical search application
Authors: J.D. Ransohoff, K.Y. Sarin
Journal: British Journal of Dermatology (2016)

One in twenty Google web searches are related to medical conditions1 indicating the prominent role of the internet as a resource for medical information. Indeed, 72% of internet users report searching online for medical conditions; 77% began with Google, Bing, or Yahoo.2 While 53% additionally sought physician consultation, 46% did not.3 Responding to its place in the medical community, in 2015 Google partnered with academic, government, and business-based ventures to develop “health cards” for searched disorders, and, in summer 2016, debuted a “related conditions” generator, suggesting diagnoses related to input disorders or symptoms.

This article is protected by copyright. All rights reserved.
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC
Authors: Andrea Notarpaolo, Richard Layese, Paolo Magistri, Maria Gambato, Michele Colledan, Giulia Magini, Lucia Miglioresi, Alessandro Vitale, Giovanni Vennarecci, Cecilia D Ambrosio, Patrizia Burra, Fabrizio Di Benedetto, Stefano Fagiuoli, Marco Colasanti, Giuseppe Maria Ettorre, Arnoldo Andreoli, Umberto Cillo, Alexis Laurent, Sandrine Katsahian, Etienne Audureau, Françoise Roudot-Thoraval, Christophe Duvoux
Journal: Journal of Hepatology (2016)
Corrigendum to “Variants of the adiponectin gene and diabetic microvascular complications in patients with type 2 diabetes” [Metab. Clin. Exp. 62 (2013) 677–685]
Authors: Eun Yeong Choe, Hye Jin Wang, Obin Kwon, Kwang Joon Kim, Bum Seok Kim, Byung-Wan Lee, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang, Christos S. Mantzoros
Journal: Metabolism (2016)
EphB4/EphrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins
Authors: Lin Li, Na Xu, Xuan Zhou, Yuling Li, Qisi Lu, Ziyuan Lu, Jixian Huang, Bolin He, Chengyun Pan, Qifa Liu, Liu Xiaoli
Journal: Blood (2015)
Centrosome Aberrations, Disturbed Mitotic Spindle Formation and G1 Arrest in Normal and Leukemic Cells Treated with the SRC/ABL Inhibitor Dasatinib.
Authors: Alice Fabarius, Michelle Giehl, Alwin Kraemer, Oliver Frank, Martin C. Mueller, Peter Duesberg, Tanja Lahaye, Claudia Schoch, Rudiger Hehlmann, Wolfgang Seifarth, Andreas Hochhaus
Journal: Blood (2006)
Clinical Features of Patients with ASXL1 and ASXL2 Mutations in Pediatric Acute Myeloid Leukemia
Authors: Genki Yamato, Norio Shiba, Kenichi Yoshida, Kentaro Ohki, Myoung-ja Park, Yusuke Hara, Daisuke Tomizawa, Manabu Sotomatsu, Takashi Taga, Souichi Adachi, Akio Tawa, Keizo Horibe, Hirokazu Arakawa, Seishi Ogawa, Yasuhide Hayashi
Journal: Blood (2014)
Long-Term Remission (&gt;3 years) after Rituximab Monotherapy Used for Patients with Relapsed Indolent Non-Hodgkin Lymphomas (NHL)
Authors: Anne-Sophie Michallet, Florence Beckerich, Fadhela Bouafia-Sauvy, Daniel Espinouse, Gilles Salles, Bertrand Coiffier
Journal: Blood (2014)
Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Pateints (pts) with Advanced Chronic Lymphoctic Leukemia (CLL): A Comparative Study.
Authors: Antonio Jimenez, Mohamed I. Farhat, Stephanie A. Gregory, Mohamad Kassar, Alla Gimelfarb, Marta Batus, Julie Nangia, Neel Shah, Parameswaran Venugopal, Melissa L. Larson, Kent W. Christopherson, Henry C. Fung
Journal: Blood (2007)
Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).
Authors: Michael Herold, Rita Pasold, Stefanie Srock, Sabine Neser, Dietger Niederwieser, Andreas Neubauer, Gottfried Dölken, Ralph Naumann, Thomas Fietz, Mathias Freund, Robert Rohrberg, Klaus Hoeffken, Astrid Franke, Thomas H. Ittel, Erika Kettner, Ursula Haak, Ullrich Mey, Christian Klinkenstein, Michael Assmann, Ullrich von Gruenhagen, Klaus Dachselt, Helga Schwenke, Dorothee Bleyl, Heiner Wolf, Sabine Hahnfeld, Franz-Adolph Hoffmann, Volker Lakner, Peter Richter, Detlev Hähling, H. H. Wolf, Henning Eschenburg, M.-R. Clemens, Norbert Grobe
Journal: Blood (2004)
Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect® CLL Disease Registry
Authors: Jeff Sharman, Christopher R Flowers, Mark Weiss, David Grinblatt, Charles Farber, Neil Kay, Thomas Kipps, Nicole Lamanna, Chris Pashos, Ian W Flinn, Mark Kozloff, Susan Lerner, Arlene S Swern, Kristen A Sullivan, Thomas K. Street, Michael Keating
Journal: Blood (2011)
MSI2 and TGFβR1 Expression Levels in CML Patients and Hematopoietic Cell Lines
Authors: Jaspal S Kaeda, Simone Bonecker, Iris von Wunsch-Rolshoven, Frauke Ringel, Michaela Schwarz, Bernd Dörken, Ilana Zalcberg, Philipp le Coutre
Journal: Blood (2014)
P0069 : Risk factors for metabolic syndrome after liver transplantation: What has changed over time
Authors: E. Vanni, R. Ibrahim Kamal Jouness, S. Mirabella, A. Marengo, A. Milan, C. Rosso, V. Boano, E. Mosso, C. Di Stefano, E. Nada, L Mezzabotta, M. Rizzetto, M. Salizzoni, R Romagnoli, E. Bugianesi
Journal: Journal of Hepatology (2015)
Localization of transforming growth factor beta 1 (TGFβ1) and Smad-4 in dysplastic human cervix
Authors: Jonathan Privette, David L. Tait, D. P. Shackelford, Heather L. Gregory, Charles A. Hodson
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

5272 

Abnormal regulation of the TGFβ family of proteins and their Smad mediators has been reported in some reproductive tract tumors including cervical cancer. Smad proteins mediate the action of TGFβs. This mediation involves the binding of Smad-4 with another Smad protein family member. This complex migrates to the cell nucleus where it acts to regulate gene expression. The diversity of Smads and TGFβs allows for multiple biological responses. In this study we compared the distribution TGFβ1 and Smad-4, one of its common mediators, in normal and dysplastic human cervix. Tissue samples from subjects with Papanicoloau smears that indicated mild to moderate dysplasia were examined. Slides were prepared for immunocytochemical localization of TGFβ1 and Smad-4 and H&E staining to grade the dysplasia by the Bethesda system. The primary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and the second antibodies were obtained from Vector Diagnostics (Burlingame, CA). TGFβ1 and Smad-4 levels were graded on a 0-3 scale with 0 indicating staining equal to negative control. Levels 1–3 indicated low, medium and intense staining. Staining intensity was compared to non-immune serum control slides. Dysplastic regions of the cervix were also compared to staining patterns in normal areas of the cervix. The dysplasias varied from mild to severe. In the normal cervical epithelium TGFβ1 was localized most strongly (+2) in the keratinized superficial layers of the cervical epithelium. In dysplastic areas TGFβ1 was at levels below +1 intensity. Smad-4 was expressed more widely in normal cervical epithelia. Intense (+3) Smad-4 staining was found in the nuclei of cervical epithelium at all levels from deep to superficial. In contrast, in dysplastic areas, Smad-4 was reduced. We found nuclear staining only in the basal cell layer. In more apical cells the nuclei were not stained and cytoplasm staining was reduced. Smad proteins are localized to the nuclei when TGFB signaling is active. Nuclear staining did not occur in dysplastic regions. These results suggest active roles for Smad-4 and TGFB1 in differentiation of normal cervical epithelia and their possible deregulation in dysplasia. We chose Smad-4 for our study because this protein is involved in the action of all TGFβs. However, different Smad-4 complexes can have similar or antagonistic actions, and in future studies we will examine the distributions of the other Smad proteins and TGFβs in the cervix. Our goal is to clarify the roles of Smad proteins and TGFβs in normal cervical epithelial differentiation and determine whether these proteins are deregulated in dysplastic tissue.
JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis.
Authors: Giovanni Barosi, Valentina Poletto, Margherita Massa, Rita Campanelli, Laura Villani, Elisa Bonetti, Gianluca Viarengo, Paolo Catarsi, Catherine Klersy, Vittorio Rosti
Journal: Blood (2012)
A Recombinant Human Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Shows Selective Cytotoxicity against Myeloid Leukemia Cells and CD123-Positive Leukemic Stem Cells.
Authors: Varghese Palath, Rohini Vekhande, Andreia Lee, Jason Williams, Ling Zhang, Alan F List, Andrew Boyd, Martin Lackmann, Andrew M Scott, Daniela Cilloni, Geoffrey T. Yarranton, Christopher Bebbington
Journal: Blood (2009)
Deferiprone Has a Dose-Dependent Effect on Liver Iron Concentration
Authors: Alessia Pepe, Tommaso Casini, Liana Cuccia, Francesco Sorrentino, Rosamaria Rosso, Paolo Ricchi, Aurelio Maggio, Maria Giovanna Neri, Maria Chiara Resta, Valentina Vinci, Vincenzo Positano, Antonella Meloni
Journal: Blood (2015)
NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant
Authors: Kotaro Shide, Yohei Nakaya, Takuro Kameda, Haruko Shimoda, Tomonori Hidaka, Yoko Kubuki, Keiko Katayose, Takuya Matsunaga, Junko Homan, Takashi Kotera, Hiroshi Shibayama, Haruna Naito, Kazuya Shimoda
Journal: Blood (2010)
Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations
Authors: Jennifer E Amengual, Maximilian Lombardo, Kelly M Zullo, Paul M. Johannet, Sathyen A Prabhu, Gonzalez Yulissa, Luigi Scotto, Ying Wei, Jimmy Duong, Owen A. O'Connor
Journal: Blood (2015)